PTAB ‘almost always wrong’ on Fintiv trial dates, research reveals
The US Patent Trial and Appeal Board (PTAB)’s dependence on trial dates to help it determine whether to apply the controversial NHK-Fintiv rule to inter partes (IPR) review petitions is flawed, according to research.
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
23 September 2021 Plans are unfolding for new legislation to erode the power of the US Patent Trial and Appeal Board to reject inter partes reviews under the controversial NHK-Fintiv rule, Senator Patrick Leahy has announced.
23 March 2021 Change is afoot at the US Patent Trial and Appeal Board and—to the chagrin of petitioners—the pendulum has swung decidedly in favour of patent owners.